Advertisement

Cancer Immunology, Immunotherapy

, Volume 34, Issue 2, pp 103–110 | Cite as

Tumour rejection after adoptive transfer of line-10-immune spleen cells is mediated by two T cell subpopulations

  • P. A. Steerenberg
  • E. Geerse
  • W. H. De Jong
  • R. Burger
  • R. J. Scheper
  • W. Den Otter
Original articles

Summary

The growth of line-10 tumours in naive guinea pigs is prevented by adoptive transfer of spleen cells that are hyperimmune to this hepatocellular carcinoma. To study the T cell subpopulations responsible for the adoptive transfer of immunity, various cell populations were removed from immune spleen cells using monoclonal antibodies (mAbs) and magnetic microspheres. Spleen cell subpopulations were identified by mAb after flow cytometry and rosette formation with the magnetic microspheres. mAb CT5 was confirmed to be a pan T cell marker, while the CT6 (anti-T-suppressor/cytotoxic) and CT7 (anti-T-cell) markers were present on two different T cell subpopulations. So our results show that CT7 mAb cannot be used as a pan T cell marker as was published previously. Moreover, the mAb H155 (anti-T-helper/inducer) reacted with the same T cell subpopulation recognized by CT7. So we designated this H155/CT7-positive subpopulation as T helper/inducer cells. Removal of the CT6-, CT7-, or the H155-positive T cells from the immune spleen cells resulted in loss of the in vitro poliferative response to line-10 tumour protein and tuberculin purified protein derivative (PPD). The H155/CT7(anti-T-helper/inducer)-positive spleen cells did not express MHC class II antigens as determined by mAb 25E3. In most experiments, elimination of MHC-class-II-positive cells did not change the in vitro proliferative response to line-10 protein, whereas the response to tuberculin PPD was completely abrogated. Immune spleen cells after depletion of CT6-, CT7- or H155-positive cells, failed to transfer immunity. However, after depletion of MHC-class-II-antigen-positive cells the line-10 immunity was still present, whereas the immune response to tuberculin PPD was lost. In conclusion, our data indicate that immunity to the line-10 tumour is the result of a cooperation between at least two different T cell subpopulations, the T helper/inducer (CT7/H155) cells and the T suppressor/cytotoxic cells (CT6). If this is a common feature, then the therapeutic approach of in vitro expanded TIL cells should take into consideration the requirement of two T cell subsets.

Key words

T helper cells Tumour rejection MHC Line-10-hepatoma Spleen cells 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Antoniou AV, Parker D, Turk JL, Tan BTG, Scheper RJ (1986) Immunocytochemical identification and quantitation of mononuclear cells in the meninges during the development of chronic relapsing experimental allergic encephalomyelitis (CREAE) in guinea pig. Cell Immunol 97: 386Google Scholar
  2. 2.
    Burger R, Shevach EM (1980) Monoclonal antibodies to guinea pig Ia antigens: II. Effect on alloantigen-, antigen- and mitogen-induced T lymphocyte proliferation in vitro. J Exp Med 152: 1011Google Scholar
  3. 3.
    Burger R, Scher I, Sharrow SO, Shevach EM (1984) Non-activated guinea pig T cells and thymocytes express Ia antigens: FACS analysis with alloantibodies and monoclonal antibodies. Immunology 51: 93Google Scholar
  4. 4.
    Burger R, Schrod L, Schaefer H (1986) Functionally relevant membrane proteins of human and guinea pig T lymphocytes. Mol Immunol 23: 1149Google Scholar
  5. 5.
    Chou T, Bertera S, Chang AE, Shu S (1988) Adoptive immunotherapy of microscopic and advanced visceral metastases with in vitro sensitized lymphoid cells from mice bearing progressive tumors. J Immunol 141: 1775Google Scholar
  6. 6.
    De Jong WH, Steerenberg PA, Kreeftenberg JC, Tiesjema RH, Kruizinga W, Van Noorle Jansen LM, Ruitenberg EJ (1984) Experimental screening of BCG preparations produced for cancer immunotherapy: safety immunostimulating and antitumor activity of four consecutively produced batches. Cancer Immunol Immunother 17: 18Google Scholar
  7. 7.
    De Jong WH, Van de Plas MMT, Steerenberg PA, Kruizinga W, Ruitenberg EJ (1985) Selective localization of tumor immune spleen cells at the tumor challenge site after adoptive transfer of line 10 tumor immunity in strain 2 guinea pigs. J Immunol 134: 2032Google Scholar
  8. 8.
    De Jong WH, Steerenberg PA, Van de Plas MMT, Kruizinga W, Ruitenberg EJ (1985) T cell involvement in adoptive transfer of line 10 tumor immunity in strain 2 guinea pigs. J Natl Cancer Inst 75: 483Google Scholar
  9. 9.
    Dye ES, North RJ, (1984) Specificity of the T cells that mediate and suppress adoptive immunotherapy of established tumors. J Leukocyte Biol 36: 27Google Scholar
  10. 10.
    Forbes JT, Nakao Y, Smith RT (1975) Tumor-specific immunity to chemically induced tumors. Evidence for immunological specificity and shared antigenicity in lymphocyte response to soluble tumor antigens. J Exp Med 141: 1181Google Scholar
  11. 11.
    Forni G, Shevach EM, Green I (1976) Mutant lines of guinea pig L2C leukemia: I. Deletion of Ia alloantigens with a loss in immunogenicity of tumor-associated transplantation antigens. J Exp Med 144: 1067Google Scholar
  12. 12.
    Kemshead JT, Health L, Gibson FM, Katz F, Richmond F, Treleaven J, Ugelstad J (1986) Magnetic microspheres and monoclonal antibodies for the depletion of neuroblastoma cells from bone marrow: experience, improvements and observations. Br J Cancer 54: 771Google Scholar
  13. 13.
    Kradin RL, Krunick JT, Lazarus DS, Preffer FI, Dubinett SM, Pinto CE, Gifford J, Davidson E, Grove B, Callahan RJ, Strauss HW (1989) Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. Lancet 18: 577Google Scholar
  14. 14.
    Lea T, Vartdal F, Davies C, Ugelstad J (1985) Magnetic monosized polymer particles for fast and specific fractionation of human mononuclear cells. Scand J Immunol 22: 207Google Scholar
  15. 15.
    Maas RA, Dullens HFJ, De Jong WH, Den Otter W (1989) Immunotherapy of mice with a large burden of disseminated lymphoma with low-dose interleukin 2. Cancer Res 49: 7037Google Scholar
  16. 16.
    McPhee CA, Milton JI, Thomson AW (1988) Flow cytometric analysis of lymphocyte populations in guinea pig blood and spleen. Ia antigen-expression and the effects of immunosuppressive agents. Int Arch Allergy Appl Immunol 87: 275Google Scholar
  17. 17.
    Meltzer MG, Leonard EJ, Rapp HJ, Borsos T (1971) Tumor specific antigen solubilized by hypertonic potassium chloride. J Natl Cancer Inst 47: 703Google Scholar
  18. 18.
    Meltzer MS, Oppenheim JJ, Litterman BH, Leonard EJ, Rapp HJ (1971) Cell-mediated tumor immunity measured in vitro and in vivo with soluble tumor specific antigens. J Natl Cancer Inst 49: 727Google Scholar
  19. 19.
    Mulé JJ, Rosenstein M, Shu S, Rosenberg SA (1985) Eradication of a disseminated syngeneic mouse lymphoma by systemic adoptive transfer of immune lymphocytes and its dependence upon a host component(s) Cancer Res 45: 526Google Scholar
  20. 20.
    Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seip CA, Simpson CG, White DEA (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin 2 or high dose interleukin 2 alone. N Engl J Med 316: 889Google Scholar
  21. 21.
    Rosenstein M, Eberlein TJ, Rosenberg SA (1984) Adoptive immunotherapy of established syngeneic solid tumors: role of T lymphoid subpopulations. J Immunol 132: 2117Google Scholar
  22. 22.
    Schäfer H, Burger R (1991) Identification and functional characterization of guinea pig CD4: antibody binding tranduces a negative signal on T cell activation. Immunol 72: 261Google Scholar
  23. 23.
    Schäfer H, Müller B, Bader A, Schenkel J, Burger R (1989) Analysis of guinea pig leukocyte antigens using interspecies T cell hybrids. J Immunol Methods 118: 169Google Scholar
  24. 24.
    Shu S, Steerenberg PA, Hunter JT, Evans CH, Rapp HJ (1981) Adoptive immunity to the guinea pig line 10 hepatoma and the nature of in vitro lymphoid tumor cell interaction. Cancer Res 41: 399Google Scholar
  25. 25.
    Shu S, Fonseca LS, Hunter JT, Rapp HJ (1983) Mechanisms of immunological eradication of a syngeneic guinea pig tumor: II. Effect of methotrexate treatment and T cell depletion of the recipient on adoptive immunity. Transplantation 35: 56Google Scholar
  26. 26.
    Spiess PJ, Yang JC, Rosenberg SA (1987) The in vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2. J Natl Cancer Inst 79: 1067Google Scholar
  27. 27.
    Steerenberg PA, De Jong WH, Geerse E, Beuvink A, Scheper RJ, Den Otter W, Ruitenberg EJ (1990) Major-histocompatibility-complex-class-II positive cells and interleukin-2-dependent proliferation of immune T cells are required to reject carcinoma cells in the guinea pig. Cancer Immunol Immunother 31: 297Google Scholar
  28. 28.
    Tan BTG, Ekelaar F, Cuirink J, Rimmelzwaan G, De Jonge AJR, Scheper RJ (1985) Production of monoclonal antibodies defining guinea pig T cell surface markers and a strain 13 Ia-like antigen: the value of immunohistological screening. Hybridoma 4: 115Google Scholar
  29. 29.
    Ward BA, Shu S, Chou T, Perry-Lalley D, Chang AE (1988) Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma. J Immunol 141: 1047Google Scholar
  30. 30.
    Weger RA De, Van Loveren H, Vandebriel RJ, Parmentier HK (1989) Sequential activity of γ-δ T cell receptor bearing lymphocytes, specific T cell factors, and α-β T-cell receptor bearing T-cells: a hypothesis. Thymus 14: 19Google Scholar
  31. 31.
    Zbar B, Bernstein ID, Barlett GL, Hanna MG Jr, Rapp HJ (1972) Immunotherapy of cancer: regression of intradermal tumors and prevention of lymph node metastases after intralesional injection of living mycobacterium bovis. J Natl Cancer Inst 49: 119Google Scholar

Copyright information

© Springer-Verlag 1991

Authors and Affiliations

  • P. A. Steerenberg
    • 1
  • E. Geerse
    • 1
  • W. H. De Jong
    • 1
  • R. Burger
    • 2
  • R. J. Scheper
    • 3
  • W. Den Otter
    • 1
    • 4
  1. 1.Laboratory for PathologyNational Institute of Public Health and Environmental ProtectionBilthovenThe Netherlands
  2. 2.Robert Koch InstituteBundesgesundheitsamtBerlinGermany
  3. 3.Pathological InstituteFree University HospitalAmsterdamThe Netherlands
  4. 4.Department of PathologyAcademisch Ziekenhuis UtrechtUtrechtThe Netherlands

Personalised recommendations